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ABSTRACT 44 
 45 
Pathogenicity assessment of DNA variants in disease genes to explain their clinical consequences is 46 
an integral component of diagnostic molecular testing. The International Society for Gastrointestinal 47 
Hereditary Tumors (InSiGHT) has developed specific criteria for the interpretation of mismatch repair 48 
(MMR) gene variants. Here, we performed a systematic investigation of 24 MLH1 and MSH2 49 
variants. The assessments were done by analyzing population frequency, segregation, tumor 50 
molecular characteristics, RNA effects, protein expression levels and in vitro MMR activity. 51 
Classifications were confirmed for 15 variants and changed for 3, and for the first time determined for 52 
6 novel variants. Overall, based on our results we propose the introduction of some refinements to the 53 
InSiGHT classification rules. The proposed changes have the advantage of homogenizing the 54 
InSIGHT interpretation criteria with those set out by the Evidence-based Network for the 55 
Interpretation of Germline Mutant Alleles (ENIGMA) consortium for the BRCA1/BRCA2 genes. We 56 
also observed that the addition of only few clinical data was sufficient to obtain a more stable 57 
classification for variants considered as “likely pathogenic” or “likely non pathogenic”. This shows 58 
the importance of obtaining as many as possible points of evidence for variant interpretation, 59 
especially from the clinical setting. 60 
 61 
 62 
INTRODUCTION 63 
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 64 
Lynch syndrome (LS) (MIM# 120435) is the most common form of inherited colorectal and 65 
endometrial cancer, predisposing also to other gastrointestinal (GI) (stomach, small bowel, biliary 66 
tract, pancreas) and non-GI cancers (urinary tract, ovary and others). The syndrome is transmitted as 67 
an autosomal dominant trait, and caused by constitutional defects in the mismatch repair (MMR) 68 
genes MLH1 (MIM# 120436), MSH2 (MIM# 609309) MSH6 (MIM# 600678) and PMS2 (MIM# 69 
600259) [Lucci-Cordisco et al., 2003; Lynch & De la Chapelle, 2003]. Detection of a constitutional 70 
loss-of-function variant in an MMR gene provides diagnostic confirmation of LS and is essential for 71 
the identification of at-risk members in LS families through predictive testing. This is especially 72 
important for LS care, since carriers of MMR gene pathogenic variants can benefit from different risk 73 
reducing options, including stringent surveillance protocols, prophylactic surgery, and 74 
chemoprevention [Vasen et al., 2013].  75 
 76 
A major challenge in the diagnosis and management of LS is the frequent occurrence of variants of 77 
uncertain significance (VUS) in the MMR genes. Depending on the gene, about 1/5th to 1/3rd of DNA 78 
sequence variants identified during the course of LS clinical testing are of uncertain significance 79 
[Sijmons et al., 2013], limiting risk reduction and management options in probands and preventing 80 
their use in predictive gene testing in relatives. 81 
 82 
The classification of DNA sequence variants identified in MMR and other cancer predisposition genes 83 
is recommended to be based on data from multiple sources, including clinical observations, tumor 84 
pathology studies and several RNA and protein based functional assays [Couch et al., 2008; Hofstra et 85 
al., 2008; Spurdle et al., 2008; Tavtigian et al., 2008a; Richards et al., 2015]. A number of in silico 86 
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programs have also been devised to assist with the prediction of functional consequences of inherited 87 
MMR gene alterations [Tavtigian et al., 2008b; Thompson et al., 2013b; Niroula & Vihinen, 2015]. 88 
 89 
Recently, the International Society for Gastrointestinal Hereditary Tumors (InSiGHT) has developed 90 
criteria for the interpretation of MMR gene variants, with the aim to improve the clinical utility of 91 
genetic testing for LS. A systematic clinical classification of all variants contained in InSiGHT locus 92 
specific databases (http://insight-group.org/variants/database/) was performed, based on a 93 
multifactorial bayesian quantitative approach and/or on stringent combinations of qualitative clinical 94 
and functional data [Thompson et al., 2014]. Variants were classified using a 5-tier system devised for 95 
cancer predisposing genes [Plon et al., 2008]. 96 
 97 
In the present study, we assessed the pathogenicity of 24 MMR gene variants using an extensive 98 
combination of RNA and protein-based functional assays, segregation studies, and tumor analyses. 99 
We were able to classify 6 novel variants as well as to confirm or refine the classification of 18 100 
variants previously assessed by InSiGHT. Overall, we show the necessity of using different analyses 101 
in VUS classification and discuss their specific value and status in the interpretation process.  102 
 103 
 104 
MATERIALS AND METHODS 105 
 106 
Genetic variants, patients and samples  107 
The variants assessed in this study were detected in a single laboratory in families fulfilling the 108 
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Bethesda criteria [Vasen, 2005] ascertained through cancer family clinics from 2002 to 2011. Overall, 109 
57 MMR gene variants (25 MLH1 and 32 MSH2), excluding well established polymorphisms, were 110 
detected in a total of 56 families. Variants that were clearly disease causing (ie truncating, splicing 111 
alterations, or large rearrangements), as well as established polymorphisms, were not considered. 112 
Exceptions were some alleles that, despite being currently considered polymorphic, were not clearly 113 
classified at the time of their detection; these included MLH1 c.1558+14G>A, and MSH2 c.380A>G 114 
and c.1511-9A>T, whose assessment was useful for the validation of the variables investigated for 115 
classification. Overall, we evaluated 24 MMR gene variants, 13 MLH1 and 11 MSH2, identified in 37 116 
unrelated families. All variants were single nucleotide substitutions at the genomic level. Based on 117 
their positions in the DNA sequence and predicted effects, they could be divided into the following 118 
groups: 12 aminoacid substitutions (8 in MLH1 and 4 in MSH2), 1 MLH1 potential splice site change 119 
affecting the first exonic position and also potentially causing an aminoacid substitution, 4 120 
synonymous exonic nucleotide substitutions (1 MLH1, 3 MSH2), and 7 intronic changes outside the 121 
most conserved positions of the splice site consensus sequences (4 MLH1 and 3 MSH2). Six variants 122 
(4 MLH1 and 2 MSH2) were previously unreported and therefore not assessed by InSiGHT.  123 
 124 
Peripheral blood leukocyte (PBL) samples were collected from 76 and 16 subjects for DNA and RNA 125 
extractions, respectively. Furthermore, lymphoblastoid cell lines (LCLs) were established from 7 126 
variant carriers. Forty-nine paraffin-embedded tumor specimens were obtained from 42 carriers of 23 127 
different variants.  128 
 129 
The study was approved by the Institutional Ethical Board of the Careggi University Hospital, 130 
Florence. Informed consent was obtained from all patients for the use of specimens and 131 
clinical/pathological data for research purposes. 132 
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 133 
Molecular analyses 134 
The complete coding sequence and flanking exon–intron borders of the MLH1 and MSH2 genes were 135 
investigated by direct sequencing on genomic DNA. The presence of MLH1 and MSH2, as well as of 136 
EPCAM (MIM# 185535), genomic rearrangements and the methylation status of the MLH1 promoter 137 
were investigated by Multiplex Ligation-dependent Probe Amplification (MLPA), as previously 138 
described [Crucianelli et al., 2014]. Values lower than 0.15 were assumed as a cut-off for normal 139 
methylation levels according to previous studies [Gylling A et al., 2007; Crucianelli et al., 2014]. 140 
 141 
The identified MLH1 and MSH2 variants have been submitted to the InSiGHT MMR gene variant 142 
database (http://www.insight-group.org/variants/database/). Variants were defined according to the 143 
Human Genome Variation Society (HGVS) recommendations [den Dunnen et al., 2016]. DNA variant 144 
numbering is based on the MLH1 and MSH2 cDNA sequences (GenBank accession numbers 145 
NM_000249.2 and NM_000251.1, respectively) with the A of the ATG translation–initiation codon 146 
numbered as +1. Aminoacid numbering starts with the translation initiator methionine as +1. 147 
 148 
To investigate the presence of the p.Val600Glu (V600E) hotspot mutation, BRAF (MIM# 164757) 149 
exon 15 was directly sequenced in 7 tumor samples of MLH1 variant carriers, using previously 150 
reported primers and conditions [Mancini et al., 2010].  151 
 152 
Loss of heterozygosity (LOH) analysis of the regions containing the identified variants was performed 153 
on matched leukocyte and tumor tissues from 19 probands by analysis of direct sequencing 154 
electropherograms [Janssen et al., 2011; Janssen et al., 2012].  155 
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 156 
Microsatellite instability and immunohistochemical analyses  157 
A total of 47 tumor samples and matched normal mucosa or PBLs from 40 patients were evaluated for 158 
microsatellite instability (MSI) using a 5-mononucleotide marker panel [Suraweera et al., 2002; 159 
Buhard et al., 2006; Giunti et al., 2009]. Tumors were classified into three categories according to the 160 
proportions of markers showing instability: MSI-H (high-level MSI), MSI-L (low-level MSI) and 161 
MSS (microsatellite stable), which have ≥ 30 – 40 %, > 0 % – < 30 – 40 %, and 0 % unstable markers, 162 
respectively [Boland et al., 1998]. Immunohistochemical (IHC) analysis of MMR protein expression 163 
was performed on paraffin-embedded tumor tissue sections from 42 samples, as previously described 164 
[Roncari et al., 2007].  165 
 166 
Allelic frequencies in control chromosomes  167 
To assess frequencies of the 24 MLH1 and MSH2 variants in control chromosomes, one hundred and 168 
sixty DNA samples from anonymized healthy Italian blood donors with no history of colorectal 169 
cancer among 1st degree relatives and from the same region of origin (Tuscany) of most of the patients 170 
were analyzed by direct sequencing. In addition, the Exome Aggregation Consortium database (ExAC 171 
Browser (Beta), http://exac.broadinstitute.org/, 04/2016 accessed) was interrogated, excluding the 172 
Cancer Genome Atlas (TGCA) data. 173 
 174 
Co-segregation with phenotype and multifactorial likelihood analysis 175 
Co-segregation analysis was performed for 11 variants in 16 families; in these, 24 affected carrier 176 
relatives, in addition to probands, were identified. The variants were detected by direct sequencing. 177 
Multifactorial likelihood analysis was performed for 14 variants for which sufficient data were 178 
  
 
This article is protected by copyright. All rights reserved. 
 
9 
available, as described previously [Thompson et al. 2013a; Thompson et al. 2013b]. Briefly, a 179 
probability of pathogenicity based on variant location or in silico scoring of missense substitutions is 180 
combined with likelihood ratios (LR) for segregation and tumour characteristics (MSI/BRAF status) 181 
to derive a posterior probability of pathogenicity.  182 
 183 
mRNA splicing analysis  184 
Total RNA was extracted from the 7 cycloheximide-treated and untreated LCLs established from 185 
MLH1 or MSH2 variant carriers, using RNeasy® Plus Mini Kit (Qiagen, Hilden, D). Cycloheximide 186 
(Sigma-Aldrich, Saint Louis, MO, USA) was added at 10µg/ml to the medium 4 hr before harvesting 187 
the cells to prevent degradation of unstable transcripts by nonsense-mediated decay (NMD). cDNA 188 
was synthesized using TaqMan Reverse Trascription Kit (Applied Biosystems, Foster City, CA, 189 
USA). Primers and conditions used for cDNA amplification are available upon request. PCR products 190 
were analyzed on agarose gels, and individual bands, corresponding either to the full length or to the 191 
aberrantly spliced transcripts were excised and eluted using the QIAquick Gel Extraction Kit (Qiagen, 192 
Hilden, Germany) before amplification and direct sequencing. All RT-PCR experiments were 193 
performed in duplicate. Since alternative splicing is commonly observed for MLH1 and MSH2 194 
[Genuardi et al. 1998], to improve the detection and interpretation of splicing aberrations, eight 195 
control samples were also analyzed [Thompson et al., 2015]. 196 
 197 
Allele-specific expression (ASE) analysis 198 
Allele-specific expression (ASE) was investigated by Single Nucleotide Primer Extension (SNuPE) in 199 
10 patients heterozygotes for the coding SNPs rs1799977 (MLH1 c.655G>A) or rs4987188 (MSH2 200 
c.965G>A, as previously described [Crucianelli et al., 2014]. Total RNA was extracted from blood 201 
samples collected into PAXgene Blood RNA tubes (PreAnalytiX, Qiagen, Hilden, Germany), using 202 
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the PAXgene Blood RNA Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 203 
instructions. Samples from heterozygotes for the same SNPs who had no additional MLH1 and MSH2 204 
sequence change were used as controls [Perera et al., 2010; Pastrello et al., 2011]. ASE was calculated 205 
after measuring peak heights in heterozygous samples [Castellsagué et al., 2010]. Values included in 206 
the 0.8-1.2 range were assumed as a cut-off for normal ASE according to previous studies [Renkonen 207 
et al., 2003; Castellsagué et al., 2010; Perera et al., 2010]. All experiments were carried out in 208 
triplicate and two independent replicates of all experiments were performed. Control heterozygotes 209 
for the MLH1 or MSH2 exonic polymorphisms (rs1799977 and rs4987188, respectively) were 210 
included in each experiment.  211 
 212 
Minigene splicing assay 213 
Splicing assays were performed by comparing the splicing pattern of WT and mutant minigenes 214 
transiently expressed in HeLa cells [Soukarieh et al., 2016]. Two different vectors were used in the 215 
minigene splicing assay: pCAS2 or pSPL3m [Soukarieh et al., 2016], as specified. Except for 2 216 
contructs (MSH2 c.2006-6T>C and c.2081T>C), minigenes were prepared by first PCR-amplifying 217 
wild-type (WT) and mutant genomic segments from patients’ DNA using forward and reverse primers 218 
mapping approximately at 150 nucleotides upstream and downstream the exon of interest, 219 
respectively. Primer sequences are available upon request. The PCR products were then inserted into 220 
the intron of pCAS2 to generate splicing reporter minigenes as previously described [Tournier et al., 221 
2008]. Minigenes carrying the single variants MSH2 c.2006-6T>C and MSH2 c.2081T>C (present in 222 
cis in patient genomic DNA) were prepared by site-directed mutagenesis by using a two-stage overlap 223 
extension PCR method [Ho et al., 1989].  The psPL3m construct carrying MLH1 c.301G>A was 224 
generated by transferring the insert from the previously described minigene 225 
pCAS1.MLH1.exon3.c.301G>A [Tournier et al., 2008]. 226 
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 227 
Protein stability and vitro MMR activity analyses 228 
Altogether 9 MLH1 and MSH2 missense variations were introduced into the MLH1 and MSH2 229 
cDNAs cloned into a pFastBac1 vector (Invitrogen, Carlsbad, CA, USA), using a PCR-based site-230 
directed mutagenesis kit according to manufacturer´s instructions (QuikChange Lightning®Site-231 
directed mutagenesis Kit, Stratagene, La Jolla, CA, USA). The mutated constructs were sequenced 232 
(ABIPrism 3100 Genetic Analyzer; Applied Biosystems, Foster City, CA, USA) prior to protein 233 
production. Primer sequences and PCR parameters are available upon request. 234 
 235 
Recombinant baculoviruses were generated by Bac-to-Bac system (Invitrogen, Carlsbad, CA, USA) 236 
and proteins were produced in Spodoptera frugiperda (Sf9) insect cells as described earlier [Nyström-237 
Lahti et al., 2002; Kariola et al, 2002; Ollila et al., 2006]. For protein production Sf9 cells were co-238 
infected with MLH1 and PMS2 viruses to yield MutLα heterodimers, or MSH2 and MSH6 viruses to 239 
yield MutSα heterodimers. The total protein extracts (TE) were prepared as previously described 240 
[Nyström-Lahti et al., 2002; Kariola et al., 2002]. 241 
 242 
The expression levels of produced protein variants were studied by Western blot analysis. The 243 
proteins were blotted onto nitrocellulose membranes (Hybond, PVDF, Amersham Pharmacia biotech, 244 
Uppsala, Sweden) and visualized with anti-MLH1 (BD Biosciences/Pharmingen, San Diego, CA, 245 
USA, clone 168-15) (0.5 µg/ml), anti-PMS2 (Calbiochem/Oncogene Research, San Diego, CA, USA, 246 
Ab-1) (0.2 µg/ml), anti-MSH2 (Calbiochem, San Diego, CA, USA, MSH2- Ab1, NA-26) (0.2 μg/ml) 247 
and anti-MSH6 (BD Transduction Laboratories, Lexington, KY, USA, clone 44) (0.02 μg/ml) 248 
monoclonal antibodies. To estimate the MMR protein level in the extracts, α-tubulin was used as a 249 
loading control (anti-α-tubulin; Sigma, Louis, MO, USA, DM1A) (0.2 µg/ml). 250 
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 251 
The repair efficiencies (R%) of the recombinant protein variants were analyzed by complementing the 252 
MMR-deficient nuclear extracts (NE) of HCT116 or LoVo cells (American Type Culture Collection, 253 
Manassas, VA, USA) with the Sf9 TEs containing overexpressed MLH1 or MSH2 proteins [Nyström-254 
Lahti et al., 2002; Kantelinen et al., 2012] according to the protocol previously described [Kantelinen 255 
et al., 2012]. Seventy-five µg of NE was incubated with TE including in each sample comparable 256 
amounts of MutLα or MutSα, respectively, and with an excess amount (100 ng) of the heteroduplex 257 
DNA substrate. R% was calculated as an average of three independent experiments using GeneTools 258 
3.08 (SynGene, Cambridge, England). The relative R% was calculated in respect to the WT control 259 
[Drost et al., 2010; Kantelinen et al., 2012]. 260 
 261 
 262 
 263 
Clinical classification of variants 264 
The 5 class system for clinical classification recommended by the International Agency for Research 265 
on Cancer (IARC) working group on the interpretation of DNA sequence variants in cancer 266 
predisposition genes was used [Plon et al., 2008]. Class 5 and 4 include definitely pathogenic and 267 
likely pathogenic variants, respectively; when observed in a proband, they provide confirmation of LS 268 
diagnosis, so that relatives can be consequently offered predictive testing. Variants assigned to class 1 269 
and 2 correspond to definitely and likely neutral/not pathogenic (or of low clinical impact) sequence 270 
changes, respectively; their detection is not followed by further clinical testing in the family. Finally, 271 
class 3 includes all those variants whose clinical and/or functional effects cannot be determined, due 272 
to either insufficient (e.g. detection in a single family) or contradictory evidence (ie discordant results 273 
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from similar in vitro assays performed in different laboratories); these are also called variants of 274 
uncertain (or unknown) significance (VUS).  275 
 276 
 277 
RESULTS 278 
 279 
Population frequency 280 
We first verified variant allele frequencies in control populations (Table 1). Previous classifications 281 
performed by InSiGHT relied on frequencies reported in the 1000 Genomes Project database 282 
(http://www.1000genomes.org/), in addition to data published or reported by single centers on local 283 
populations. In this study we used values from the Exome Aggregation Consortium (ExAC), which is 284 
a more comprehensive dataset and which also incorporates the 1000 Genomes data. We also tested 285 
160 Italian control subjects for 20 variants. 286 
 287 
Four variants (MLH1 c.1558+14G>A; MSH2 c.380A>G, c.1511-9A>T and c.2006-6T>C) that 288 
reached minor allele frequencies > 0.01 had previously been classified as Class 1-not pathogenic 289 
based on population frequency data alone [Thompson et al., 2014], and were subjected to further 290 
analyses to verify consistency across different points of evidence. The frequency of MSH2 c.380A>G 291 
in phase 1 of the 1000 Genomes Project, which had been originally used for classification, was 0.02, 292 
while the currently reported frequency in ExAC is slightly lower, 0.00692. Of note, the frequencies of 293 
MLH1 c.1039-8T>A were 0.00155 in ExAC and 0.02187 in 160 Italian controls, respectively. This 294 
difference is likely accounted for by a low quality of calling in the ExAC population, as suggested by 295 
the following observations: (i) it is called in less than 80% of individuals in ExAC; (ii) the variant was 296 
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found to be in linkage disequilibrium with MLH1 c.1558+14G>A in the Italian population; and (iii) 297 
MLH1 c.1558+14G>A had similar polymorphic frequencies in ExAC and in Italian controls (0.03948 298 
versus 0.02187). 299 
 300 
Tumor pathology data 301 
Analyses performed on tumors included microsatellite instability (MSI), MMR 302 
immunohistochemistry (IHC), BRAF p.Val600Glu somatic mutation, MLH1 promoter methylation, 303 
and loss of heterozygosity (LOH) (Table 1).   304 
 305 
MSI and/or IHC data were available for 23/24 and 22/24 variants, respectively (Table 1). These 306 
included 12/13 predicted missense changes, for 6 of which > 2 tumors were investigated. Results 307 
indicative of in vivo MMR inactivation (MSI-H status and/or lack of expression of the protein 308 
encoded by the gene carrying the constitutional variant) were observed for 7 predicted missense 309 
substitution variants: MLH1 c.301G>A p.(Gly101Ser), c.779T>G p.(Leu260Arg), c.1421G>C 310 
p.(Arg474Pro), c.1814A>C p.(Glu605Ala), and MSH2 c.2081T>C p.(Phe694Ser) and c.2087C>T 311 
p.(Pro696Leu), as well as for the potential splice variant MSH2 c.2006G>T. Results indicative of in 312 
vivo and in vitro MMR proficiency (MSS status, normal MMR protein expression and proficient 313 
functional assays) were obtained on 2 missense variants, MLH1 c.1043T>C p.(Leu348Ser) and MSH2 314 
c.244A>G p.(Lys82Glu). Discordant MSI and IHC results were observed for the missense variants 315 
MLH1 c.2041G>A p.(Ala681Thr) and c.2059C>T p.(Arg687Trp) in tumors from different 316 
individuals; for  both variants 1 MSI-H tumor showed normal IHC staining, while 1 MSS sample was 317 
associated with lack of MLH1 expression. 318 
 319 
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BRAF and/or MLH1 promoter analyses were performed on tumor samples for 9 variants (Table 1). 320 
The BRAF p.Val600Glu mutation was detected in two MLH1-negative tumors from carriers of the 321 
MLH1 variants c.1421G>C p.(Arg474Pro) and c.1743G>A p.(Pro581=), respectively. MLH1 322 
epigenetic defects could be tested only for the tumor from the carrier of the c.1743G>A variant, which 323 
however did not show MLH1 promoter hypermethylation. Four additional samples had both BRAF 324 
p.Val600Glu and MLH1 promoter methylation tested: both analyses were negative in 3 MSI-H 325 
samples from carriers of MLH1 c.779T>G p.(Leu260Arg) carriers and in 1 MSI-H sample from a 326 
c.2041G>A p.(Ala681Thr) carrier. 327 
 328 
LOH analysis was performed for 14 variants, 8 MLH1 and 6 MSH2 (Table 1). Loss of the variant 329 
allele was detected in tumors from carriers of 3 different MLH1 variants: c.1217G>A p.(Ser406Asn), 330 
c.1421G>C p.(Arg474Pro) and c.1732-19T>C.  331 
 332 
RNA analyses 333 
The MSH2 variant c.2006G>T, which is currently assigned to Class 5 based on evidence of a major 334 
splicing defect, was associated with complete exclusion of exon 13 in the minigene assay (Fig. 1), but 335 
with only partial skipping in the LCL from a carrier (Fig. 2A and 2B). Both alleles at position 2006 336 
were detected in the full-length cDNA product from the LCL (Fig. 2C and 2D). Partial exon 13 loss 337 
was also detected in blood samples drawn in PAXgene tubes from the patient above and from 2 338 
additional individuals carrying MSH2 c.2006G>T investigated in another laboratory in France, as well 339 
as in a LCL established from one of these French carriers (data not shown).  340 
 341 
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Three other variants (MLH1 c.301G>A and c.1039-8T>A; MSH2 c.2006-6T>C) were associated with 342 
partial exon skipping (Table 2; Fig. 1; Supp. Fig. S1-S2) in patient samples, in the ex vivo minigene 343 
assay, or in both. These involved in all cases known alternatively spliced transcripts [Genuardi et al., 344 
1998; Thompson et al., 2015]. Interestingly, for MSH2 c.2006-6T>C partial exon 13 exclusion was 345 
only detected by the minigene assay (Fig. 1) but not in the patient sample (Tournier et al., 2008), 346 
further suggesting that the minigene assay may overestimate the splicing defect for this exon. On the 347 
other hand, in this study partial skipping of exon 12 was observed in lymphoblastoid cells (data not 348 
shown) but not with the minigene assay for MLH1 c.1039-8T>A (Supp Fig. S2). The latter result is in 349 
accordance with previous findings obtained for this variant by minigene assay [Petersen et al., 2013].  350 
 351 
In addition, the minigene assay showed that Class 5-pathogenic MLH1 c.301G>A p.(Gly101Ser) is 352 
associated with loss of the use of an alternative splice site (Supp Fig. S3); while the clinical 353 
significance of this finding cannot be established based on the minigene result only, the variant allele 354 
should produce only the canonical transcript.  355 
 356 
None of the 10 variants tested by the SNuPE assay showed evidence of allelic expression imbalance, 357 
consistent with the splicing assay results (Table 2). 358 
 359 
Mismatch repair activity and protein expression analyses  360 
An in vitro MMR complementation assay based on the synthesis of MMR protein in Spodoptera 361 
frugiperda (Sf9) insect cells was performed in MMR-defective human cell lines for 9 coding variants 362 
(Table 2). Three of the five MMR defective protein variants (MLH1 p.Leu260Arg; MSH2 363 
p.Phe694Ser and p.Pro696Leu were found to be unstable in vitro (Fig. 3). Loss of MMR activity 364 
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(relative activity < 1%) was demonstrated for 5 variants: MLH1 p.Gly101Ser and p.Leu260Arg, and 365 
MSH2 p.Gly669Val, p.Phe694Ser and p.Pro696Leu. The remaining four variants, MLH1 366 
p.Leu348Ser, p.Arg474Pro, p.Glu605Ala, and MSH2 p.Lys82Glu, were all stable in the transient 367 
expression assay and MMR proficient.  368 
 369 
Four other missense variants, MLH1 p.Ser406Asn, p.Ala681Thr, p.Arg687Trp, and MSH2 370 
p.Asn127Ser, had been previously shown to be proficient in the MMR activity assay, although two of 371 
them, MLH1 p.Ala681Thr and p.Arg687Trp, showed discordant protein instability results across 372 
different studies (Table 2). 373 
 374 
Clinical data, multifactorial analysis and variant classification 375 
Family history types, co-occurrence of other MMR gene variants, and the components and results 376 
multifactorial analysis are shown in Supp. Tables S1-S2.  377 
 378 
Multifactorial analysis was performed for 14 variants. Using quantitative analysis (based on 379 
multifactorial posterior probability) and/or assessment of qualitative criteria, variants were classified 380 
according to the 5-tier system proposed by InSiGHT (Table 3) [Thompson et al., 2014]. Four of the 381 
six novel variants (MLH1, c.1732-19T>C and c.1743G>A; MSH2 c. 244A>G and c.2442T>G) were 382 
assigned to Class 2-likely not pathogenic. Of note, one novel variant, MLH1 c.1814A>C 383 
p.(Glu605Ala), is in class 4-likely pathogenic according to multifactorial analysis based only on 2 384 
available values, a 0.7 prior probability calculated in silico, and  a single MSI-H CRC not expressing 385 
the MLH1 protein.  The remaining novel variant, MLH1 c.1043T>C p.(Leu348Ser) is in Class 3-VUS 386 
due to insufficient evidence. 387 
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 388 
The previous InSiGHT assignment of MSH2 c.2006G>T to Class 5-pathogenic based on RNA 389 
splicing data was confirmed by the results of multifactorial analysis in this study (Table 3).  390 
 391 
The classification made by InSiGHT was changed for 3 variants after the addition of novel 392 
segregation and molecular tumor data. MLH1 c.301G>A p.(Gly101Ser), originally in Class 4-likely 393 
pathogenic, was upgraded to Class 5-pathogenic, while variants MSH2 c.1387-8G>T and c.1737A>G 394 
p.(Lys579=) were moved from Class 2-likely not pathogenic to Class 1-not pathogenic.  395 
 396 
Previous classifications of the other 15 variants were supported by the data obtained. Results of novel 397 
RNA analyses performed in this study were in agreement with the assignment to Class 1-not 398 
pathogenic of intronic MLH1 variants c.1039-8T>A and c.1558+14G>A.  Insufficient evidence to 399 
attain a clinically actionable category was available for MLH1 c.1421G>C p.(Arg474Pro), even 400 
though novel data from tumor studies brought down the posterior probability of pathogenicity from 401 
0.51 to 0.094.  402 
 403 
 404 
DISCUSSION 405 
 406 
The ultimate purpose of genetic testing for LS and other cancer predisposition syndromes is to reduce 407 
cancer morbidity and mortality through the implementation of specific preventive options for carriers 408 
of disease causing variants. Interpreting the significance of DNA variants identified in the diagnostic 409 
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laboratory is an integral component of clinical DNA testing. The interpretation process is complex, as 410 
several independent datasets must be taken into account. Recently, recommendations for clinical 411 
classification of MMR gene variants have been formulated [Thompson et al., 2014]. We have 412 
performed a thorough investigation of 24 MMR gene sequence variants identified in a single center in 413 
order to assess their clinical relevance, using points of evidence that are included in the InSiGHT 414 
recommendations, as well as additional potential classification components. Our findings confirm the 415 
overall validity of the InSiGHT criteria and suggest that the interpretation process could be improved 416 
by introducing some adjustments. 417 
 418 
Overall, our results provide support to or improve previous classifications for the 18 variants that had 419 
already been assessed by InSiGHT (http://insight-group.org/variants/classifications). For 3 of these 420 
variants (MLH1 c.301G>A; MSH2 c.1387-8G>T and c.1737A>G), a more stable classification, either 421 
from Class 4-likely pathogenic to Class 5-pathogenic or from Class 2-likely not pathogenic to Class 1-422 
not pathogenic, was achieved using novel clinical and molecular data. These changes do not affect 423 
cancer prevention strategies, since the same clinical recommendations apply to Class 5 and 4 and 424 
Class 2 and 1, respectively [Plon et al., 2008]. However, assignments to Class 5 and 1 can be 425 
considered definitive, since the likelihood that a variant in either of these categories will be moved to 426 
a class associated with different clinical advice is very low [Plon et al., 2008]. The IARC/InSiGHT 427 
interpretation criteria advise to consider research testing of further samples/relatives to try and obtain 428 
definitive classifications for Class 4-likely pathogenic and Class 2-likely not pathogenic variants 429 
[Plon et al. 2008; Thompson et al. 2014], and our results demonstrate the practical importance of this 430 
recommendation. For all 3 variants the classification was based on multifactorial analysis, and in all 431 
cases the class switch was made possible by the incorporation of few novel data on tumor 432 
characteristics and/or segregation, highlighting the relevance of collecting these types of information. 433 
 434 
  
 
This article is protected by copyright. All rights reserved. 
 
20 
The novel variants MLH1 c.1814A>C p.(Glu605Ala) and MSH2 c.244A>G p.(Lys82Glu) were in 435 
Class 4-likely pathogenic and Class 2-likely not pathogenic, respectively, following multifactorial 436 
analysis. For both variants only one clinical observation, that is, molecular information obtained on a 437 
single tumor sample (Table 1 and Supp. Table S2), is available. The Evidence-based Network for the 438 
Interpretation of Germline Mutant Alleles (ENIGMA) in the BRCA1/BRCA2 (MIM# 113705 and 439 
MIM# 600185) genes recommends that variants attaining thresholds for assignment to clinically 440 
actionable classes by multifactorial analysis with limited contribution from clinical or laboratory 441 
evidence be considered of uncertain significance until further evidence is accrued 442 
(http://enigma.consortium.org/documents/ENIGMA_Rules_2015_03_26.pdf). We propose to adopt 443 
this recommendation also for the MMR genes, especially when there is apparent discordance between 444 
functional and clinical evidence, such as for MLH1 p.(Glu605Ala). In particular, for MLH1 variants 445 
additional evidence from BRAF and/or promoter methylation tumor testing could be used to reinforce 446 
the evidence in favor of pathogenicity. 447 
 448 
The partially discordant RNA splicing results between the minigene assay and analyses of patient 449 
derived samples obtained in this study for MSH2 c.2006G>T suggest that the splicing alteration may 450 
not be the only or the major inactivation mechanism for MSH2 c.2006T. Indeed, the functional in 451 
vitro assay showed reduced repair activity of the protein encoded by the variant allele, p.669Val and 452 
the variant could be assigned to Class 5 also based on multifactorial analysis. However, complete 453 
absence of c.2006T allele in full-length transcript.in patient RNA, together with total exon 13 454 
exclusion in a minigene assay, was observed in another study [van der Klift et al., 2015]. Therefore, 455 
further studies will be needed to clarify the mechanisms underlying pathogenicity of MSH2 456 
c.2006G>T. At the same time, the interpretation criteria for RNA analyses should be reconsidered 457 
based on these apparently inconsistent results.  458 
 459 
  
 
This article is protected by copyright. All rights reserved. 
 
21 
Minor effects on splicing were observed either on patient RNA or by the minigene assay in this study 460 
for the Class 1-not pathogenic variants MLH1 c.1039-8T>A and MSH2 c.380A>G and c.2006-6T>C. 461 
All are in Class 1 based on population frequency only, confirming that they have no major clinical 462 
effects [Genuardi et al., 1998; Thompson et al., 2015].  463 
 464 
None of the other variants were found to be associated with significant splicing anomalies. Lack of 465 
abnormal splicing products was important to assign MLH1 c.307-19A>G, c.1732-19T>C and 466 
c.1743G>A, and MSH2 c. 2442T>G p.(Leu814=) to Class 2-likely not pathogenic. Two of them, 467 
MLH1 c.307-19A>G and c.1743G>A also had population frequencies ~1/5,000 and ~1/10,000, 468 
respectively. According to the InSiGHT criteria, synonymous or deep intronic variants for which 469 
splicing assays do not show alterations should be considered as Class 2-likely not pathogenic. One of 470 
the combinations required for assignment of a variant to Class 1-not pathogenic includes all of the 471 
following points of evidence: allelic frequency 0.01%-1%, lack of co-segregation with disease, 472 
estimated risk <1.5 determined by case-control studies, and presence of molecular features not 473 
compatible with involvement of the gene carrying the variant in ≥ 3 tumors; this criterion applies to 474 
all types of variants, regardless of their nature and prior probability of altering gene function. Since 475 
intronic and synonymous variants have a low a priori likelihood of affecting gene processing, 476 
combinations of any of the above evidences (ie, lack of segregation, population frequency, low 477 
estimated risk, and molecular characteristics) and normal splicing patterns could reasonably be 478 
considered sufficient for assignment to Class 1. Interestingly, the association of intronic location or 479 
synonymous coding nucleotide substitution and absence of mRNA aberrations demonstrated by in 480 
vitro assays has been proposed by the ENIGMA consortium as a criterion for assignment of variants 481 
in the BRCA1/BRCA2 genes to Class 1-not pathogenic 482 
(http://enigmaconsortium.org/documents/ENIGMA_Rules_2015-03-26.pdf). Data from our study 483 
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indicate that it would be justified to consider homogenization of the Class 1 criteria for 484 
intronic/synonymous substitutions between the ENIGMA and InSiGHT consortia. 485 
 486 
Nine missense variants were investigated by in vitro MMR assay based on the production of MSH2 or 487 
MLH1 proteins in Sf9 insect cells and subsequent complementation of human MMR deficient cell 488 
lines. The same assay had been previously used for three other missense substitutions found in our 489 
series [Raevaara et al., 2005; Ollila et al., 2008; Christensen et al., 2009; Kansikas et al., 2011], while 490 
one variant - MLH1 c.1217G>A p.(Ser406Asn) - had been tested with two different mammalian repair 491 
assays. All five MMR deficient variants (MLH1 p.(Gly101Ser) and p.(Leu260Arg); MSH2 492 
p.(Gly669Val), p.(Phe694Ser) and p.(Pro696Leu)) are in Class 5-pathogenic, supporting the 493 
classifications based on multifactorial analysis. Of note, the aminoacids replaced in MSH2 494 
p.(Phe694Ser) and p.(Pro696Leu) are located nearby in the ATPase domain, indicating that this 495 
region is particularly sensitive to structural changes; this suggestion is reinforced by the observation 496 
that none of the 29 reported MSH2 exon 13 missense changes have been so far assigned to Class 1-not 497 
pathogenic or Class 2-likely not pathogenic by InSiGHT 498 
(http://chromium.lovd.nl/LOVD2/colon_cancer/variants.php?select_db=MSH2&action=search_all&s499 
earch_Variant%2FExon=13&search_MutCol=%3E&search_Variant%2FDNA=&search_Variant%2F500 
RNA=&search_Variant%2FProtein=&search_Patient%2FPhenotype%2FDisease=&search_Patient%501 
2FReference=).  502 
 503 
MLH1 c.2041G>A p.(Ala681Thr) and c.2059C>T p.(Arg687Trp) are assigned to Class 5-pathogenic 504 
despite the results of the functional assays, which show inconclusive data on protein expression and 505 
normal MMR activity, with discordant observations across different studies. However, both are 506 
associated with an abundance of clinical data allowing them to overcome the Class 5-pathogenic 507 
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posterior probability threshold using multifactorial analysis. At the same time discordant tumor 508 
pathology findings, including samples that were MSS and/or expressed MLH1, have also been 509 
reported for both variants. It will be interesting to verify the degree of phenotypic expression 510 
associated with these two variants. By analogy with equivocal functional results obtained on the 511 
BRCA1 variant p.Arg1699Gln [Spurdle et al., 2012] they might be considered as candidate 512 
intermediate risk variants. Notably, other MLH1 missense substitutions located in proximity of these 513 
variants are associated with proficient repair but reduced or inconclusive protein expression data; 514 
these include for instance the Class 5-pathogenic c.1942C>T p.(Pro648Ser) and c.1943C>T 515 
p.(Pro648Leu), and the Class 3-VUS c.1918C>T p.(Pro640Ser), c.1919C>T p.(Pro640Leu), 516 
c.1976G>A p.(Arg659Gln), c.2027T>G p.(Leu676Arg), and c.2027T>C p.(Leu676Pro). Therefore 517 
variants located in this region of the MLH1 protein may cause functional impairment through reduced 518 
expression/stability and/or other as yet to be determined mechanisms not directly affecting repair 519 
activity. 520 
 521 
While LOH is an important silencing mechanism of the wild type allele [Alemayehu et al., 2007], so 522 
far it has not been considered as a point of evidence for MMR gene variant classification by InSiGHT. 523 
This is due to several reasons, including multiple observations of loss of variant pathogenic alleles in 524 
cancers from MMR gene carriers and technical difficulties, ie, due to the potential presence of MSI 525 
hampering analysis of LOH using microsatellite markers [Hofstra et al., 2008]. The findings from this 526 
study, especially the observation of loss of the variant allele in samples from carriers of Class 1-not 527 
pathogenic and Class 2–likely not pathogenic variants confirm that LOH should be considered with 528 
caution for the interpretation of variant pathogenicity in the MMR genes. Studies on large series are 529 
needed to assess the usefulness of this marker and its predictive value.   530 
 531 
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The evaluation of multiple clinical parameters and functional assays undertaken in this study allows 532 
refining the strategy for the clinical classification of MMR gene variants. Intronic and synonymous 533 
variants that cannot be tested in the in vitro MMR assay should be assessed for effects on RNA 534 
processing, by detection of aberrant transcripts (in the presence of NMD inhibitors) and allele-specific 535 
expression  (in the absence of NMD inhibitors). We suggest that, when no major alteration is 536 
observed, the variant could be assigned to Class 1-not pathogenic, even without further evidence 537 
(from ie, segregation and tumor characteristics), as stated by ENIGMA for BRCA1 and BRCA2. The 538 
underlying rationale is that the probability that an intronic variant with no documented splicing 539 
aberration will cause high tumor risk is very low, < 1/1,000. 540 
 541 
For potential missense variants, concordant evidence in favour or against pathogenicity should be 542 
derived both from functional assays - RNA first, and if normal, protein - and clinical data. Given the 543 
importance of obtaining segregation and molecular tumor results for the purpose of variant 544 
classification, any attempt should be made to test additional patients and samples, especially from 545 
carriers of missense variants which are usually more difficult to classify compared to silent and 546 
intronic changes.  547 
 548 
Finally, classifications obtained by multifactorial analysis should be supported by multiple data 549 
points; this could be achieved by requiring a minimum threshold or different points of evidence from 550 
clinical and tumor data to allow assignment to a clinically actionable class.  551 
 552 
humu23117-sup-0001-SuppMat.docx 553 
Supplementary Information Figure S1.  Identification of MSH2 splicing effects by using a 554 
splicing minigene reporter assay. (A) Structure of the pCAS2-MSH2 minigenes. Boxes represent 555 
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exons and lines in between indicate introns. MSH2 segments are shown in dark colour. Splicing 556 
events detected in the minigene assay are indicated by the dotted lines and further described on the 557 
right. (B) Analysis of the splicing pattern of wild-type and mutant pCAS2-MSH2 minigene 558 
transcripts. Wild-type and mutant minigenes, as indicated, were transfected into HeLa cells and the 559 
minigene transcripts were analyzed by RT-PCR. The image shows a 2% agarose gel stained with 560 
ethidium bromide, visualized by exposure to ultraviolet light under conditions of non-saturating 561 
exposure. The identities of the RT-PCR products are shown both on the left and on the right of the 562 
gel. Results are representative of 3 independent experiments. M, size marker (100 bp DNA ladder, 563 
New England Biolabs); pCAS2, empty vector; WT, wild-type. 564 
Supplementary Information Figure S2.  Analysis of the impact on splicing of MLH1 variants by 565 
using a minigene reporter assay. (A) Structure of the pCAS2-MLH1 minigenes. Boxes represent 566 
exons and horizontal lines in between indicate introns. MLH1 segments are shown in dark colour. 567 
Splicing events detected in the minigene assay are indicated by the dotted lines and further described 568 
on the right. (B) Analysis of the splicing pattern of wild-type and mutant pCAS2-MLH1 minigene 569 
transcripts. Wild-type and mutant minigenes, as indicated, were transfected into HeLa cells and the 570 
minigene transcripts were analyzed by RT-PCR. The image shows a 2% agarose gel stained with 571 
ethidium bromide, visualized by exposure to ultraviolet light under conditions of non-saturating 572 
exposure. Results are representative of 3 independent experiments. M, size marker (100 bp DNA 573 
ladder, New England Biolabs); pCAS2, empty vector; WT, wild-type. 574 
Supplementary Information Fig. S3. MLH1 c.301G>A alters the alternative splicing pattern of 575 
MLH1 exon 3 in the minigene splicing assay. (A) Structure of the pSPL3m-MLH1ex3 minigene. 576 
Boxes represent exons and horizontal lines in between indicate introns. The MLH1 segment is shown 577 
in dark colour. Splicing events detected in the minigene assay are indicated by the dotted lines. (B) 578 
Analysis of the splicing pattern of wild-type and mutant pSPL3m-MLH1ex3 minigene transcripts. 579 
Wild-type and mutant minigenes, as indicated, were transfected into HeLa cells and the minigene 580 
transcripts were analyzed by RT-PCR as described under Materials and Methods. The image shows a 581 
2% agarose gel stained with ethidium bromide, visualized by exposure to ultraviolet light under 582 
conditions of non-saturating exposure. The identities of the RT-PCR products are shown on the left 583 
and below the gel. (C) Usage of the reference 5’ss and a5’ss of MLH1 exon 3 (NM_000249.3 and 584 
NM_001167617.1, respectively) in the WT and mutant contexts. The upper panel shows in silico 585 
predictions for the effect of c.301G>A on the strength of the 5’ splice site of MLH1exon 3 586 
(predictions obtained with 5 different algorithms, as described in Soukarieh et al., 2016). The bottom 587 
panel shows the sequence of the RT-PCR products indicated by the star (heteroduplexes) and purified 588 
from the gel shown in B. 5’ss, 5’splice site; a5’ss, alternative 5’ splice site; Δ5 nts, deletion of the last 589 
5 nucleotides of MLH1 exon 3. 590 
Supplementary Information Table S1. Clinical data and co-occurrence of multiple variants in families with MMR 591 
gene variants. 592 
Supplementary Information Table S2. Segregation and multifactorial likelihood analysis for the investigated MMR 593 
gene variants. 594 
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 890 
Figure 1.  Identification of MSH2 exon 13 splicing alterations by using a splicing minigene 891 
reporter assay. (A) Structure of the pCAS2-MSH2ex13 minigene. Boxes represent exons and 892 
horizontal lines in between indicate introns. The MSH2 segment is shown in dark colour. Splicing 893 
events detected in the minigene assay are indicated by the dotted lines and further described on the 894 
right. (B) Analysis of the splicing pattern of wild-type and mutant pCAS2-MSH2ex13 minigene 895 
transcripts. Wild-type and mutant minigenes, as indicated, were transfected into HeLa cells and the 896 
minigene transcripts were analyzed by RT-PCR as described under Materials and Methods. The 897 
image shows a 2% agarose gel stained with ethidium bromide, visualized by exposure to ultraviolet 898 
light under conditions of non-saturating exposure. The identities of the RT-PCR products are shown 899 
on the right. Results are representative of 3 independent experiments. Marker, 100 bp DNA ladder 900 
(New England Biolabs); pCAS2, empty vector; WT, wild-type; *, heteroduplexes.  901 
 902 
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41 
Figure 2. Splicing analysis by RT-PCR on cDNA from a LCL established from a carrier of 903 
MSH2 variant c.2006G>T.  (A) Gel electrophoresis of cDNA PCR products obtained using primers 904 
located in MSH2 exons 12 and 14. MW: molecular weight marker (100 bp ladder). The upper band 905 
corresponds to the full length mRNA product, the fainter lower band to the isoform lacking exon 13. 906 
The arrow next to the asterisk shows the heteroduplex formed by the two PCR products. (B) 907 
Schematic representation of MSH2 mRNA encompassing exons 12-14 and of the two splicing 908 
products detected in the LCL sample. (C) Electropherogram of the sequence of the ∆13 cDNA 909 
product. (D) Electropherogram of the sequence of the full-length cDNA product showing presnece of 910 
both alleles at c.2006G>T (the reverse strand is shown).  911 
 912 
Figure 3. Expression and functional analyses of the 5 MLH1 and 4 MSH2 missense variants. (A-913 
B) Western Blot analysis of total protein extracts from Sf9 cells coinfected with baculovirus 914 
constructs expressing PMS2 wild-type protein (PMS2 WT) with either MLH1 WT or with MLH1 915 
variant, and MSH6 WT with either MSH2 WT or MSH2 variant, and showing instability of proteins 916 
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42 
MLH1 p.Leu260Arg, MSH2 p.Phe694Ser, and MSH2 p.Pro696Leu. α-tubulin was used as a loading 917 
control. (C-D) Repair efficiency (R%) of the recombinant MutLα (MLH1+PMS2) and Mutsα 918 
(MSH2+MSH6) protein variants measured in the in vitro MMR assay and calculated as the ratio of 919 
double digested DNA relative to total DNA added to the reaction, and showing functional deficiency 920 
in MLH1 p.Gly101Ser, MLH1 p.Leu260Arg, MSH2 p.Gly669Val, MSH2 p.Phe694Ser, and MSH2 921 
p.Pro696Leu. R% corresponds to the assay results shown in the figure, X 3R% denotes the average of 922 
three independent experiments with standard deviations (±). Nuclear extract free MOCK and 923 
uncomplemented MMR-deficient HCT116 NE and LoVo NE serve as negative controls and HCT116 924 
and LoVo NE complemented by MutLα and Mutsα, respectively, serve as positive controls. The top 925 
fragment (3193 bp) shows the migration of unrepaired linearized G·T mismatch containing construct 926 
and the two smaller fragments (1833 bp and 1360 bp) represent the repaired and double digested 927 
fragments. (E) The relative repair % was calculated in respect to the wild type control (MutLα or 928 
MutSα respectively) set as 100 (100, X 3R%) according to Drost et al., 2010, and Kantelinen et al., 929 
2012.  930 
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Tabel 1.Population frequency and tumor molecular and immunohistochemical characteristics of MMR gene variants. 932 
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Table 2. Effects of MMR gene variants on RNA processing, protein stability and  in vitro MMR activity.  944 
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8T>A 
 partial 
loss of 
exon 12 
nt no effect 
(Peterse
n et al., 
2013; 
this 
study)  
na na 
12 c.1043T>C p.(Leu348Se
r) 
no effect no 
allelic 
imbala
nce 
no effect Stable Proficie
nt 
12 c.1217G>
A 
p.(Ser406As
n) 
no effect no 
allelic 
imbala
nce 
(Pastre
llo et 
al. 
2011 
and 
this 
study) 
no effect Stable 
(Takaha
shi et al. 
2007) 
Proficie
nt 
(Takaha
shi et al. 
2007; 
Drost et 
al. 
2010) 
13 c.1421G>C p.(Arg474Pr
o) 
nt nt no effect Stable Proficie
nt 
13i c.1558+14
G>A 
 nt nt no effect na na 
15i c.1732-  no effect nt no effect na na 
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19T>C 
16 c.1743G>
A 
p.(Pro581=) nt nt no effect na na 
16 c.1814A>
C 
p.(Glu605Al
a) 
nt no 
allelic 
imbala
nce 
no effect Stable Proficie
nt 
18 c.2041G>
A 
p.(Ala681Th
r) 
no effect 
(Jakubo
wska et 
al., 2001; 
Betz et 
al., 2010) 
no 
allelic 
imbala
nce 
no effect 
(Tournie
r et al., 
2008) 
Discord
ant 
results 
(Raevaa
ra et al., 
2005; 
Takahas
hi et al., 
2007; 
Xie et 
al., 
2010; 
Hardt et 
al., 
2011; 
Hinrichs
en et al., 
2013) 
Proficie
nt 
(Raevaa
ra et al., 
2005; 
Takahas
hi et al., 
2007; 
Hinrichs
en et al., 
2013) 
18 c.2059C>T p.(Arg687Tr
p) 
no effect 
(Jakubo
wska et 
al., 2001; 
Furukaw
a et al., 
2002; 
Auclair 
et al., 
2006; 
Arnold et 
al., 2009; 
this 
study) 
no 
allelic 
imbala
nce 
no effect Discord
ant 
results 
(Takaha
shi et al., 
2007; 
Christen
sen et 
al., 
2009)  
Proficie
nt 
(Takaha
shi et al., 
2007; 
Christen
sen et 
al., 
2009) 
MS 2 c. 244A>G p.(Lys82Glu nt no no effect Stable Proficie
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H2 allelic 
imbala
nce 
nt 
3 c.380A>G p.(Asn127Se
r) 
nt nt partial 
exclusio
n of 
exon 3  
Stable 
(Kansik
as et al., 
2011) 
Proficie
nt 
(Ollila et 
al., 
2008) 
8i c.1387-
8G>T 
 nt nt no effect 
(Tournie
r et al., 
2008) 
na na 
9i c.1511-
9A>T 
 nt nt no effect 
(Tournie
r et al., 
2008) 
na na 
11 c.1666T>C p.(Pro556=) no effect 
(Auclair 
et al., 
2006) 
nt no effect 
(Tournie
r et al., 
2008) 
na na 
11 c.1737A>
G 
p.(Lys579=) no effect 
(Auclair 
et al., 
2006) 
nt no effect 
(Tournie
r et al., 
2008) 
na na 
12i c.2006-
6T>C5 
 no effect 
(Tournie
r et al., 
2008) 
na partial 
exon 13 
exclusio
n 
(Tournie
r et al., 
2008;  
this 
study) 
na na 
13 c.2006G>
T 
reported as 
p.(Pro670Le
ufs*) 
(predicted 
missense 
partial 
exon 13 
exclusion 
(this 
study) 
nt complet
e exon 
13 
exclusio
n (van 
der Klift 
Stable Deficien
t 
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change 
p.(Gly669Va
l) 
complete 
exon 13 
exclusion  
(van der 
Klift et 
al., 2015) 
et al., 
2015; 
this 
study) 
13 c.2081T>C
5 
p.(Phe694Se
r) 
nt no 
allelic 
imbala
nce 
no effect Unstabl
e 
Deficien
t 
13 c.2087C>T p.(Pro696Le
u) 
nt no 
allellic 
imbala
nce 
no effect 
(Tournie
r et al., 
2008) 
Unstabl
e 
Deficien
t 
14 c.2442T>
G 
p.(Leu814=) nt nt no effect na na 
 946 
1 Previously unclassified variants are shown in bold. 2 nt = not tested. 3 The results shown are from this study, unless otherwise 947 
indicated. 4 In italics: results of studies using in vitro mammalian assays different from that used in the present study.5 These two 948 
variants (MSH2 c.2006-6T>C  and c.2081T>C ) were also tested in combination in the minigene assay, since they were found in linkage 949 
disequilibrium.  950 
 951 
 952 
Table 3. Clinical classification of MLH1 and MSH2 variants. 953 
 954 
GENE DNA and 
predicted 
protein change
1
 
InSiGHT 
classification2,
3 
Proposed 
classificatio
n 
Rationale for classification4 
Posterior 
probability 
of 
pathogenicit
y by 
multifactori
al analysis3 
Qualitative criteria 
MLH
1 
c.301G>A; 
p.(Gly101Ser) 
4 5 0.99740  Co-segregation 
 MSI/IHC data 
 Deficient MMR 
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function 
 Allelic 
frequency: 0 
(this study) 
 c.307-19A>G 2 2 na  Intronic 
location 
 Normal 
minigene 
splicing assay 
 MSI/IHC data 
 Allelic 
frequency: 
0.0002 (ExAc); 
0 (this study) 
 c.779T>G; 
p.(Leu260Arg) 
5 5 1  Co-segregation 
 MSI/IHC data 
 Deficient MMR 
function 
 Allelic 
frequency: 0 
(this study) 
 c.1039-8T>A 1 1 na  Intronic 
location 
 Allelic 
frequency: 
0.00155 
(ExAc); 
0.02187 (this 
study) 
 MSI/IHC data 
 No major 
splicing 
abnormalities 
 c.1043T>C; 
p.(Leu348Ser) 
 3 0.64637 Insufficient data 
(proficient MMR 
function; 1 MSS tumor; 
no major splicing 
alteration) 
 c.1217G>A; 
p.(Ser406Asn) 
1 1 < 0.00100  Allele 
frequency: 
0.00089 
(ExAc); 
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0.00333 (this 
study) 
 MSI/IHC data 
 Lack of co-
segregation 
with 
phenotype 
(combined 
segregation 
likelihood ratio 
< 0.01) 
 Co-occurrence 
of MSH2 
truncating 
variant that 
segregates 
with the 
phenotype in 
the family 
 Proficient 
MMR function 
 No major 
splicing 
abnormalities 
 Estimated risk 
from case-
control studies 
(1.5) 
 c.1421G>C; 
p.(Arg474Pro) 
3 3 0.09448 Insufficient data (no 
major splicing 
alteration; proficient 
MMR function; 1 
tumor MSI-H BRAF 
p.Val600Glu positive) 
 c.1558+14G>A 1 1 na  Intronic 
location 
 Allelic 
frequency: 
0.03948 
(ExAc); 
0.02187 (this 
study) 
 MSI/IHC data 
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 No major 
splicing 
abnormalities 
 c.1732-19T>C na 2 0.01386  Intronic 
location 
 1 MSS tumor 
 No major 
splicing 
abnormalities 
 c.1743G>A; 
p.(Pro581=) 
na 2 na  Synonymous 
coding change 
 No major 
splicing 
abnormalities 
by minigene 
assay 
 Allelic 
frequency: 
0.00008 
(ExAc); 0 (this 
study) 
 1 MSI-H MLH1-
neg BRAF 
p.Val600Glu-
pos tumor 
 c.1814A>C; 
p.(Glu605Ala) 
na 4 0.95294 MSI/IHC data  
 c.2041G>A; 
p.(Ala681Thr) 
5 5  0.99708  Co-segregation 
 MSI/IHC data 
 c.2059C>T; 
p.(Arg687Trp) 
5 5 0.99999  Co-segregation 
 MSI/IHC data 
 Homozygosity 
associated 
with 
constitutional 
mismatch 
repair 
deficiency 
syndrome 
MSH
2 
c. 244A>G; 
p.(Lys82Glu) 
na 2 0.00980  MSI/IHC data 
 Proficient 
MMR function 
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 No major 
splicing 
abnormalities 
 c.380A>G; 
p.(Asn127Ser) 
1 1 na  Allelic 
frequency: 
0.0692 (ExAc) 
 No major 
splicing 
abnormalities 
by minigene 
assay 
 Proficient 
MMR function 
 c.1387-8G>T 2 1 0.00088  Intronic 
location 
 Allelic 
frequency: 
0.00194 
(ExAc) 
 MSI/IHC data 
(> 3 tumors 
not showing 
features of 
MMR 
deficiency 
and/or MSH2 
inactivation) 
 No major 
splicing 
abnormalities 
 c.1511-9A>T 1 1 na  Intronic 
location 
 Allelic 
frequency: 
0.08400 
(ExAc); 
0.07333 (this 
study) 
 MSI/IHC data 
 No major 
splicing 
abnormalities 
by minigene 
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assay 
 c.1666T>C; 
p.(Pro556=) 
1 1 < 0.00010  Synonymous 
coding change 
 Allele 
frequency: 
0.00437 
(ExAc); 0 (this 
study) 
 MSI/IHC data 
 No major 
splicing 
abnormalities 
 c.1737A>G; 
p.(Lys579=) 
2 1 0.00021  Synonymous 
coding change 
 Allelic 
frequency: 
0.0019 (ExAc); 
0 (this study) 
 MSI/IHC data 
(> 3 tumors 
not showing 
features of 
MMR 
deficiency 
and/or MSH2 
inactivation) 
 No major 
splicing 
abnormalities 
 c.2006-6T>C 1 1 na  Intronic 
location 
 No major 
splicing 
abnormalities 
 c.2006G>T; 
reported as 
p.(Pro670Leufs
*) (predicted 
missense 
change 
p.(Gly669Val) 
5 5 0.99906  Co-segregation 
 MSI/IHC data 
 Deficient MMR 
functional test 
 Contrasting 
results of RNA 
splicing 
analyses 
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 c.2081T>C; 
p.(Phe694Ser) 
5 5 0.99990  Co-segregation 
 MSI/IHC data 
 Deficient MMR 
function 
 c.2087C>T; 
p.(Pro696Leu) 
5 5 1  Co-segregation 
 MSI/IHC data 
 Deficient MMR 
function 
 c.2442T>G; 
p.(Leu814=) 
na 2 na  Synonymous 
coding change 
 No major 
splicing 
abnormalities 
by minigene 
splicing assay 
 Co-observation 
of MSH2 Class 
5-pathogenic 
variant (phase 
unknown) 
 955 
1Variants not yet classified by InSiGHT are shown in bold. 2 For previously classified variants, the classification 956 
corresponds to that reported on http://insight-group.org/variants/classifications/. 957 
3 na = not available. 4 Classification was achieved by multifactorial analysis, qualitative criteria or both; in italics data 958 
obtained at least in part from the present study.  959 
 960 
